NCT03606967 2026-04-17
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
AstraZeneca
Hoosier Cancer Research Network
Bayer
City of Hope Medical Center
Canadian Cancer Trials Group
NRG Oncology
Cedars-Sinai Medical Center